SPOTLIGHT: FDA approves FluMist for young children
The FDA has approved MedImmune's no-needle FluMist vaccine for use in kids as young as 2; previously it could only be used in children 5 years and older. This is good news for MedImmune (and its new parent AstraZeneca), which has struggled to make FluMist a success since the drug was approved in 2003. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
